This previously published paper should have included the following “Conflict of Interest” statements for Pr Yuji Matsuzawa (YM) and Pr Takashi Kadowaki (TK):

YM has served as a consultant for Daiichi-Sankyo, Otsuka and Teijin Pharma, and has served on speakers’ bureaus for Bayer, Boehringer Ingelheim, Otsuka, Takeda and Teijin Pharma. TK has served on advisory panels for Boehringer Ingelheim, Daiichi-Sankyo, Novo Nordisk, Taisho, Takeda and Tanabe-Mitsubishi, and has served as a consultant for Boehringer Ingelheim and MSD, and has received research support from Astra Zeneca, Chugai, Daiichi-Sankyo, MSD, Ono, Sanofi, Takeda and Tanabe-Mitsubishi, and has served on speakers’ bureaus for Astellas, Astra Zeneca, Boehringer Ingelheim, Daiichi-Sankyo, Dainippon-Sumitomo, Eli Lilly, Kowa, Kyowahakko Kirin, MSD, Novartis, Ono, Sanofi, Sanwa, Taisho, Takeda and Tanabe-Mitsubishi.